Welcome to our dedicated page for Dianthus Therapeutics /DE/ SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dianthus Therapeutics /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dianthus Therapeutics /DE/'s regulatory disclosures and financial reporting.
Dianthus Therapeutics granted its SVP, General Counsel and Secretary, Adam Veness, a stock option for 100,000 shares of common stock on February 3, 2026. The option has an exercise price of $52.46 per share and was reported as directly owned.
The underlying common shares will vest in equal monthly installments over four years after January 1, 2026, as long as Veness continues serving the company on each vesting date. Following this award, he beneficially owned 100,000 derivative securities linked to Dianthus common stock.
Dianthus Therapeutics executive Simrat Randhawa, EVP and Head of R&D, reported a grant of stock options. On February 3, 2026, Randhawa received 150,000 stock options with an exercise price of $52.46 per share, all held directly.
The options relate to Dianthus common stock and begin vesting from January 1, 2026. They vest in equal monthly installments over four years, conditioned on Randhawa’s continued service with the company on each vesting date, and expire on February 3, 2036.
Dianthus Therapeutics reported a new equity award to its EVP, CFO & CBO, Ryan Savitz. On February 3, 2026, he received a stock option covering 150,000 shares of common stock with an exercise price of $52.46 per share and no cost at grant.
The option expires on February 3, 2036 and the underlying shares will vest in equal monthly installments over four years after January 1, 2026, as long as he continues serving the company on each vesting date. All 150,000 derivative securities are reported as directly owned following the transaction.
Dianthus Therapeutics CEO and President Marino Garcia reported a stock option grant. On February 3, 2026, he was awarded a Stock Option (Right to Buy) covering 355,000 shares of common stock at an exercise price of $52.46 per share.
The option was granted at no cost as a derivative security and is held directly. The underlying 355,000 shares will vest in equal monthly installments over four years after January 1, 2026, contingent on his continued service with Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. is registering up to $600,000,000 of securities that it may offer over time. The shelf registration covers common stock, preferred stock, debt securities, warrants and units, which can be issued in one or more offerings with terms set in future prospectus supplements.
Dianthus is a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases, led by its monoclonal antibody candidate claseprubart, designed to target the active form of the C1s complement protein. The company’s common stock trades on The Nasdaq Capital Market under the symbol “DNTH,” and the last reported sale price on January 27, 2026 was $50.31 per share.
The company expects to use net proceeds from any future sales primarily to fund preclinical and clinical development, working capital and general corporate purposes, and potentially to license, acquire or invest in additional product candidates.
Dianthus Therapeutics, Inc. filed a current report describing preliminary year-end liquidity. The company’s audited financial statements for the year ended December 31, 2025 are not yet available, but it expects to report approximately $514 million in cash, cash equivalents, and short-term investments as of December 31, 2025. This estimate is preliminary, unaudited, and subject to completion of year-end closing procedures, so actual results may differ materially.
The cash information is being shared in an investor presentation furnished as an exhibit, which will be used in meetings beginning January 12, 2026. The same presentation will also be used when President and CEO Marino Garcia speaks at the 44th Annual J.P. Morgan Healthcare Conference. The company notes that the presentation includes forward-looking statements and provides related cautionary language.
Dianthus Therapeutics (DNTH) reported Q3 2025 results. Revenue was $396 thousand from licensing. Research and development expense rose to $32.5 million and general and administrative expense was $8.2 million, driving a net loss of $36.8 million, or $0.97 per share.
The balance sheet strengthened following a September underwritten offering. Cash and cash equivalents were $55.984 million, with short‑term investments of $346.629 million and long‑term investments of $152.874 million. Total assets reached $577.4 million against total liabilities of $31.0 million, resulting in stockholders’ equity of $546.5 million.
In September, the company sold 7,627,879 shares at $33.00 and issued pre‑funded warrants for 1,112,121 shares at $32.999, for gross proceeds of $288.4 million, to fund development, working capital and general corporate purposes. The ATM program remains available with $160.8 million of capacity. Shares outstanding were 42,876,015 as of November 3, 2025. Management states existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financials’ issuance date.
Dianthus Therapeutics filed an 8-K stating it furnished a press release with financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1. The information is furnished under Item 2.02 and is not deemed filed under Section 18, nor incorporated by reference except if specifically referenced.
Dianthus Therapeutics (DNTH) filed an 8-K to announce it has posted an updated corporate presentation on its investor relations website. The presentation is furnished as Exhibit 99.1 and is incorporated by reference.
The company notes the presentation contains forward-looking statements and includes cautionary language directing readers to related risk considerations. This is an informational update and does not disclose transaction terms or financial results.